Generics maker Divi's Laboratories, which he founded 26 years ago, reported close to a one-third jump in net earnings to $166 million on revenue of $580 million in the year ended March 2016. The company's factory in South India was successfully inspected by the U.S. FDA in February, but its plan to build a new unit to make pharma ingredients near the coast in Andhra Pradesh State has faced opposition from local shrimp hatcheries for fear it may contaminate the seawater. The company says the concerns are unfounded as effluents will be treated before being released.